

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/005557

International filing date: 22 February 2005 (22.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/546,111  
Filing date: 19 February 2004 (19.02.2004)

Date of receipt at the International Bureau: 06 June 2005 (06.06.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1325653

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*May 24, 2005*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 60/546,111**

**FILING DATE: February 19, 2004**


**RELATED PCT APPLICATION NUMBER: PCT/US05/05557**



Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

16085 U.S. PTO  
021904

Please type a plus sign (+) inside this box 

PTO/SB/16 (02-01)  
Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EU 861355976 US

22859 U.S. PTO  
60/546111  
021904

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Andrew Hang		Hamilton Yin		Guilford, CT New Haven, CT	
<input type="checkbox"/> Additional inventors are being named on the ___ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (280 characters max)					
Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Customer Number		<input type="text"/>		<input type="checkbox"/> Place Customer Number Bar Code Label here	
OR Type Customer Number here					
<input checked="" type="checkbox"/> Firm or Individual Name		Yale University, Office of Cooperative Research			
Address		433 Temple Street			
Address					
City		New Haven		State	CT
Country		USA		ZIP	06511
		Telephone	(203) 436-8096	Fax	(203) 436-8086
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification		Number of Pages		<input type="checkbox"/> CD(s), Number	
		6			
<input type="checkbox"/> Drawing(s)		Number of Sheets		<input type="checkbox"/> Other (specify)	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE AMOUNT (\$)	
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:		25-0110		\$80.00	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input type="checkbox"/> No.					
<input checked="" type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____ NIH CA78038					

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME L. Alan Carr, Jr.

TELEPHONE

(203) 785-3074

Date 02/19/04

REGISTRATION NO.  
(if appropriate)  
Docket Number:

N/A

NYA

### USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.



# Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein

Hang Yin and Andrew D. Hamilton\*

Department of Chemistry, Yale University, PO. Box 20810, New Haven, CT 06511, USA

Received 12 August 2003; accepted 15 September 2003

**Abstract**—A group of novel Bcl-xL/Bak antagonists, based on a terephthalamide scaffold, were designed to mimic the  $\alpha$ -helical region of the Bak peptide. Good in vitro inhibition potencies in disrupting the Bak/Bcl-xL complex have been observed (terephthalamide 4,  $K_i = 0.78 \pm 0.07 \mu\text{M}$ ).

© 2004 Published by Elsevier Ltd.

Proteins in the Bcl-2 family play a critical role in determining the fate of a cell through the process of apoptosis.<sup>1</sup> Many oncogenic mutations, particularly those to p53, result in defects in DNA damage-induced apoptosis through a Bcl-2 dependent mechanism.<sup>2</sup> In addition, overexpression of Bcl-2 can inhibit the potency of many currently available anticancer drugs by blocking the apoptotic pathway.<sup>3</sup> Therefore, agents that directly mimic the death-promoting region BH3 domain of the pro-apoptotic subfamily of Bcl-2 proteins<sup>4</sup> are of potential therapeutic value.


The NMR-derived structure of the Bcl-xL/Bak BH3 domain complex indicates that the Bak peptide is an amphipathic  $\alpha$ -helix that interacts with Bcl-xL by projecting hydrophobic side chains (Val<sup>74</sup>, Leu<sup>78</sup>, Ile<sup>81</sup> and Ile<sup>85</sup>) on one face of the  $\alpha$  helix, into a hydrophobic cleft of Bcl-xL.<sup>5</sup> Several low molecular weight inhibitors of Bcl-2/Bcl-xL have been reported with the majority showing potency in the low  $\mu\text{M}$  range.<sup>6</sup> An alternative approach for identifying inhibitors is to design synthetic scaffolds that reproduce structural features of the BH3 helix region. We have previously reported functionalized terphenyls based on 1 as mimetics of the discontinuous binding epitopes of BH3.<sup>7</sup> However, the hydrophobicity of the terphenyls and their challenging syntheses prompted us to search for simpler scaffolds that could similarly mimic the side chain presentation on an  $\alpha$ -helix. Herein, we report a group of novel

Bcl-xL/Bak antagonists based on a terephthalamide scaffold, designed to mimic the  $\alpha$ -helical region of the Bak peptide. Using a fluorescence polarization assay, we have observed high in vitro inhibition potencies in disrupting the Bcl-xL/Bak complex and a significant improvement of water solubility relative to the terphenyl derivatives.

The goal of our design was to maintain the similarity between the arrangement of the i, i+4, i+7 side chains of an  $\alpha$ -helix and the substituents on 3, 2', 2'- positions on terphenyl 1,<sup>7</sup> while minimizing the structural complexity and increasing the solubility of the inhibitors. This strategy of simplifying a proven *proteomimetic* was accomplished by using terephthalamide 2 as the scaffold. The flanking phenyl rings in 1 were replaced by two functionalized carboxamide groups, which also retain a planar geometry due to the restricted rotation of the amide bonds. Figures 1A and B show, respectively, superimpositions of energy-minimized 2 on 1 ( $R_1 = R_2 = R_3 = \text{Me}$ ) with an RMS deviation value 0.34 Å and on the i, i+4, i+7 side chains of an  $\alpha$ -helix with an RMS deviation value 1.03 Å, suggesting good stereochemical similarity between both pairs.<sup>8</sup>

A modular synthesis of terephthalamide derivative 4 is shown in Scheme 1. The 2-alkoxy group was introduced by *O*-alkylation and the 1-carboxylic acid was installed through Sandmeyer reaction and Stille coupling followed by Lemieux-Johnson and PDC oxidization. The amide bond formation steps were accomplished by using standard coupling conditions.

\* Corresponding author. Tel.: +1-203-432-3221; e-mail: andrew.hamilton@yale.edu




**Figure 1.** (A) The superimposition of terphenyl 1 on terephthalamide 2. (B) Stereo view of the superimposition of 2 on the i, i+4, i+7 positions of an  $\alpha$ -helix.

Another conformational constraint in the molecule was imposed by an intramolecular hydrogen bond between the amide -NH and the alkoxy oxygen atom, to influence the position of the upper alkyl group (Fig. 2).<sup>9</sup> The intramolecular hydrogen bond was confirmed by variable temperature NMR, which showed very little change in the amide-NH resonance ( $\delta=0.54$  ppm) on heating ( $\Delta\delta=1.54$  ppm/K) or changing concentration.<sup>10</sup> As a comparison, 2-isopropylamino terephthalamide 17 showed both concentration (7.36 ppm, 0.5 M in  $\text{CDCl}_3$ ; 6.58 ppm, 0.05 M in  $\text{CDCl}_3$ ; 6.46 ppm, 0.005 M in

$\text{CDCl}_3$ , 298 K) and temperature ( $\Delta\delta=5.5$  ppb/K) dependence of the aniline proton, suggesting inter- rather than intramolecular hydrogen bonding.

Two strategies were used to orient the interacting N-alkyl group of the lower tertiary amide into the desired Z-conformation. In 3, the problem was avoided by using identical substituents on the tertiary amide nitrogen. In a second series of derivatives (5, Scheme 2), steric differentiation of the substituents favored the placement of the isobutyl group in the Z-position (Fig. 3A). The conformation of 5 in solution was probed by ROESY and NOESY  $^1\text{H}$  spectroscopy.<sup>11</sup> NOE cross peaks between  $\text{H}_b$  and the *ortho*-aryl protons were detected, while no significant NOE effect could be seen between  $\text{H}_a$  and the *ortho*- protons. However, correlations corresponding to the chemical exchange of  $\text{H}_a$  and  $\text{H}_b$  were observed in the ROESY experiment (Fig. 3B), which indicated there were two conformations of 5 existing in DMSO solution at 298 K. Furthermore, the signals of both  $\text{H}_a$  and  $\text{H}_b$ , which are split at room temperature, coalesced at 353 K. These combined experimental results suggest that both Z- and E-amide conformations are present with the Z-conformation being favored by 72% (from NMR integration), and by 8.01 kJ/mole in water solution (from MM2 energy minimization using MacroModel). The consequence of these constraints is that in low energy, accessible conformations of 5, the three substituents project from one face of the terephthalamide scaffold in a manner analogous to the terphenyl helix mimetics (e.g., Fig. 1A).<sup>7</sup>

The binding affinity of the terephthalamide molecules for Bcl-xL was assessed by a fluorescence polarization assay using a fluorescently labeled 16-mer Bak-peptide (FI-GQVGRQLAIIGDDINR-CONH<sub>2</sub>).<sup>5</sup> Displacement of this probe through competitive binding of the



**Scheme 1.** Modular synthesis of terephthalamide derivatives 3 and 4.





Figure 2.  $^1\text{H}$  NMR spectra of low field region for 4 of different concentrations.



Scheme 2. Synthesis of terephthalamide derivative 5.




Figure 3. (A) Energy minimized Z- and E- isomers of 5. (B) ROESY  $^1\text{H}$  experiments showed cross peaks corresponding to chemical exchange of Ha.

**Figure 5.** Result of the molecular-docking studies of **6** and Bcl-xL. (A) Full view. (B) Close up of an overlay of the highest-ranked binding mode and the Bak peptide. The key hydrophobic side chains of Bak are shown as stick representations.

developed. Systematic synthesis, conformational studies and fluorescence polarization binding assays were completed and sub-  $\mu$ M level in vitro affinities were observed.

### Acknowledgements

We thank the National Institutes of Health for financial support of this work.

### References and notes

- (a) Adams, J. M.; Cory, S. *Science* **1998**, *281*, 1322. (b) Reed, J. C. *Nature* **1997**, *387*, 773.
- (a) Graeber, T. G.; Osmanian, C.; Jacks, T.; Housman, D. E.; Koch, C. J.; Lowe, S. W.; Giaccia, A. J. *Nature* **1996**, *379*, 88. (b) Fearon, E. R.; Vogelstein, B. *Cell* **1990**, *61*, 759.
- Strasser, A.; Huang, D. C. S.; Vaux, D. L. *Biochim. Biophys. Acta-Rev. on Cancer* **1997**, *1333*, F151.
- Adams, J. M.; Cory, S. *Trends in Biochem. Sci.* **2001**, *26*, 61.
- Sattler, M.; Liang, H.; Nettlesheim, D.; Meadows, R. P.; Harlan, J. E.; Eberstadt, M.; Yoon, H. S.; Shuker, S. B.; Chang, B. S.; Minn, A. J.; Thompson, C. B.; Fesik, S. W. *Science* **1997**, *275*, 983.
- (a) Wang, J. L.; Liu, D. X.; Zhang, Z. J.; Shan, S. M.; Han, X. B.; Srinivasula, S. M.; Croce, C. M.; Alnemri, E. S.; Huang, Z. W. *Proc. Natl. Acad. Sci. U.S.A.* **2000**, *97*, 7124. (b) Degterev, A.; Lugovskoy, A.; Cardone, M.; Mulley, B.; Wagner, G.; Mitchison, T.; Yuan, J. Y. *Nat. Cell Biol.* **2001**, *3*, 173. (c) Tzung, S. P.; Kim, K. M.; Basanez, G.; Giedt, C. D.; Simon, J.; Zimmerberg, J.; Zhang, K. Y. J.; Hockenbery, D. M. *Nat. Cell Biol.* **2001**, *3*, 183. (d) Enyedy, I. J.; Ling, Y.; Nacro, K.; Tomita, Y.; Wu, X. H.; Cao, Y. Y.; Guo, R. B.; Li, B. H.; Zhu, X. F.; Huang, Y.; Long, Y. Q.; Roller, P. P.; Yang, D. J.; Wang, S. M. *J. Med. Chem.* **2001**, *44*, 4313. (e) Lugovskoy, A. A.; Degterev, A. I.; Fahmy, A. F.; Zhou, P.; Gross, J. D.; Yuan, J. Y.; Wagner, G. *J. Am. Chem. Soc.* **2002**, *124*, 1234.
- Kutzki, O.; Park, H. S.; Ernst, J. T.; Orner, B. P.; Yin, H.; Hamilton, A. D. *J. Am. Chem. Soc.* **2002**, *124*, 11838.
- Energy minimization and compound superimpositions were carried out using the MM2 forcefield within the MacroModel program.
- Ernst, J. T.; Becerril, J.; Park, H. S.; Yin, H.; Hamilton, A. D. *Angew. Chem.-Int. Edit.* **2003**, *42*, 535.
- Crisp, G. T.; Jiang, Y. L. *Arkivoc* **2001**, *2*, U60.
- 2-D NMR experiments were conducted with Bruker 500 Hz under following conditions: 0.1 mM 2 in DMSO at 298 K.
- Under this assay condition, the unlabeled 16-mer Bak peptide gave a  $K_d$  of 120 nM (Kutzki, O. et al., *J. Am. Chem. Soc.* **2002**, *124*, 11838, ref 10).